Seminars in Liver Disease 2002: Vol 22 Index

13 Pages·2002·3 MB·English

AUTHOR INDEX
VOLUME 22, 2002
Agarwal, Shri Ram, 43 Kodonas, Fotis, 97
Alpini, Gianfranco, 227
Amitrano, Lucio, 83 Lai, Guan-Hua, 303
Arakawa, Masahiro, 73 Larrey, Dominique, 145
LaRusso, Nicholas F., 277
Balzano, Antonio, 83 Lazenby, Audrey J., 395
Bohan, Alan, 123 Leung, Nancy, $15
Boyer, James L., 123 LeSage, Gene, 227
Brancaccio, Vincenzo, 83 Liddle, Christopher, 109, 115
Brown, Steven John, 157 Lyra, Andre C., 103
Brunt, Elizabeth M., 103
Manns, Michael P., $7, 315, 339
Chen, Xian-Ming2,7 7 Marcellin, Patrick, $33
Chitturi, Shivakumar, 169 Marzioni, Marco, 227
Crawford, James M., 213 Masuzaki, Takao, 73
Czaja, Albert J., 365 McDonald, George B., 27
McFarlane, lan G., 317
DeLeve, Laurie D., 27 Min, Albert D., 207
Desmond, Paul Vincent, 157
Di Bisceglie, Adrian M., 103 Nenopoulou, Helen, 97
Doctor, R. Brian, 263 Neuberger, James, 379
Donaldson, Peter T., 353 Nishio, Akiyoshi, 291
Drevelegas, Antonios, 97
Ohbu, Makoto, 59
Endo, Kanenori, 303 Okuda, Kunio, 1, 15, 59, 73
Esteban, Rafael, $1 Okudaira, Masahiko, 59
Farrell, Geoftrey C., 109, 185 Papadimitriou, Constantine S., 97
Feranchak, Andrew P., 251 Phinizy,J o Lynne, 227
Ferrante, Dino, 395 Pincus, Steven, 103
Fitz,J . Gregory, 211, 241, 251
Fouassier, Laura, 263 Rose, Noel R., 387
Francis, Heather, 227
Sarin, Shiv K, 43
George, Jacob, 169 Sellers, Marty J., 395
Gershwin, M. Eric, 291 Shulman, Howard M., 27
Glaser, Shannon S., 227 Sirica, Alphonse E., 303
Goodwin, Bryan, 115 Sood, Gagan, 395
Guardascione, Maria A., 83 Stedman, Catherine, 195
Strassburg, Christian P., 339
Hytiroglou, Prodromos, 97 Suriawinata, Ariet, 207
loannidis, Ioannis, 97 Valla, Dominique-Charles, 5
lordanidis, Fotis, 97 van Leeuwen, Dirk J., 395
Jaeckel, Elmar, 325 Yoon, Byung-IL, 303
Kaplowitz, Neil, 137 Zhang, Zichen, 303
Keeffe, Emmet B., 291 Zoulim, Fabien, $23
Note: Numbers preceded by S indicate pages in Volume 22, Supplement
Copyright © 2002 by Thieme Medical Publishers, Inc. , 333 Seventh Avenue, New York,N Y 10001, USA. Tel: +1(212) 5

SUBJECT INDEX
VOLU22M, E20 02
A clinical criteria in, 145-155
Acarbose, hepatotoxicity of, 168-183 eliminating (negative), 145-155
N-Acetylcysteine, for sinusoidal obstruction syndrome, 27-41 positive, 145-155
N-Acetyltransferase 2, deficiency of, and drug-related method of, 145-155
hepatotoxicity, 145-155 performance of, 145-155
Acquired immunodeficiency syndrome (AIDS). See AIDS Age, and susceptibility to adverse hepatyiacti c Gdr ug reactions,
cholangiopathy; Human immunodeficiency 145-155
virus (HIV) AIDS chol: ingiop: ithy
Actin cytoskeleton etiology of, 277-289
and cell polarity, 263-276 pathogenesis of, cryptosporidiosis and, 277-289
in cholangiocyte disease, 263-276 Albendazole, hepatotoxicity of, 157-167
in cholangiocyte function, 263-276 Alcohol abuse, and drug-related hepatotoxicity, 145-155
functions of, in epithelial cells, 263-276 Aldosterone receptor antagonist, hepatotoxicity of, 168-183
ischemia and, 263-276 Aminoglycosides, hepatotoxicity of, 157-167
and membrane structure and tension, 263-276 Amiodarone, steatohepatitis caused by, 185-194
organization of, 263-276 Amodiaquine, hepatotoxicity of, 157-167
and transporter and channel activity, 263-276 Amoxicillin, hepatotoxicity of, 157-167
and vesicular trafficking, 263-276 Amphotericin B, hepatotoxicity of, 157-167
Acyclovir, hepatotoxicity of, 157-167 Ampicillin, hepatotoxicity of, 157-167
Adefovir dipivoxil Androstane receptor, constitutive. See Constitutive
for chronic hepatitis B androstane receptor (CAR)
in HBeAg-negative disease, $33-S36 Anemia, with idiopathic portal hypertension, 59-71
in HBeAg-positive disease, S33-S36 Angiotensin-converting enzyme (ACE) inhi bitors,
lack of resistance to, $23-S31 hepatotoxicity of, 168-183
for lamivudine-resistant chronic hepatitis B Angiotensin II receptor inhibitors, hepatotoxicity of, 168-183
with compensated liver disease, S33-S36 Anorectal varices
with decompensated liver disease before or after endoscopic obliteration of, 43-58
transplant, S33-S36 with extrahepatic portal vein obstruction, 43-a n x
in HIV-coinfected patients, $33-S36 Antibiotics, hepatotoxicity of, 157-167
Adenosine receptors, 251-262 Anticoagulation
Adenosine triphosphatase (ATPase), activity of, 251-262 with extrahepatic portal vein obstruction, 43-58
Adenosine triphosphate (ATP) for hepatic vein thrombosis, 5-14
as paracrine signaling molecule, 251-262 and herbal medicines, interactions of, 195-206
and purinergic regulation of cholangiocyte transport, in prevention of sinusoidal obstruction syndrome, 27-41
251-262 Anticonvulsants, hepatotoxicity of, 168-183
release Anti-cytosol antibodies type 1, in autoimmune hepatitis,
ABC proteins and, 251-262 32932 9-351
cell volume and, 251-262 Antidepressants, hepatotoxicity of, 168-183
by cholangiocytes, 251-262 Antidiabetic agents, hepatotoxicity of, 168-183
by hepatocytes, 251-262 Antiepileptic agents, hepatotoxicity of, 168-183
kinase-dependent signaling pethways and, 251-262 Antifibrinolytic agents, for coagulation disorders, 83-96
regulation of, 251-262 Antifungal agents, hepatotoxicity of, 157-167
Adverse drug reactions Antihypertensive agents, hepatotoxicity of, 168-183
affecting liver. See a/so Hepatotoxicity, drug-related Antimicrobial agents, hepatotoxicity of, 157-167
antimicrobial agents and, 157-167 Antimitochondrial antibodies
epidemiology of, 145-155 in autoimmune hepatitis, 395-405
susceptibility to, 145-155 in primary biliary cirrhosis, 291-302
causality assessment for Antineutrophil cytoplasmic antibody (ANCA), in
chronological criteria in, 145-155 autoimmune hepatitis, 339-351
Note: Numbers preceded by S indicate pages in Volume 22, Supplement 1.
Copyright © 2002 by Thieme Medical Publishers, Inc. , 333 Seventh Avenue, New York, NY 10001, USA. Tel: [phone]
1-4 SEMINARS IN LIVER DISEASE/VOLUME 22, NUMBER 4 2002
Antinuclear antibodies definition of, 317-324
in autoimmune hepatitis, 339-351 de novo, in transplant recipients, 365-377, 379-385
and overlapI syndromes, 339-35 diagg nosis of, 339-351, 395-405
in primary biliary cirrhosis, 339-351 experimental
\ntiparasitic agents, hepatotoxicity of, 157-167 historical perspective on, 325-337
\ntiplatelet agents, and herbal medicines, interactions of, in mice, 325-337
195-206 in rabbits, 325-337
\ntipsychotics, hepatotoxicity of, 168-183 with fulminant hepatic failure, 395-405
(ntiretroviral therapy, hepatotoxicity of, 157-167 gene therapy for, 365-377
\nti-smooth muscle antibodies, in autoimmune hepatitis, genetic models of, 325-337
339-351 genetics of, 353-363
Antithrombin III, in prevention of sinusoidal obstruction advances in (future directions for), 353-363
syndrome, 27-41 histological features of, 317-324
\ntituberculosis agents, hepatotoxicity of, 157-167 historical perspective on, 317-324
Antiviral agents, hepatotoxicity of, 157-167 immunologic features of, 317-324
\poptosis liver graft dysfunction mimicking, 379-385
in cholangiocytes, 227-240 liver transplantation for, 365-377, 379-385, 395-405
defects in, and autoimmune disease, 387-394 allograft rejection in, 379-385
molecular machinery of, 137-144 chronic hepatitis after, 379-385
and necrosis, differentiation of, 137-144 contraindications to, 379-385
protection against, 137-144 immunosuppression after, 379-385, 395-405
in toxic liver injury, 137-144, 227-240 indications for, 379-385
\protinin, indications for, 83-96 timing of, 379-385
\sialoglycoprotein receptor, autoantibodies against, 339-351 nomenclature for, development of, 317-324
\spirin, hepatotoxicity of, 168-183 recurrence, post-transplant, diagnosis of, 379-385
\torvastatin, hepatotoxicity of, 168-183 relapse after remissanido dnru g withdrawal,
\TP-binding cassette (ABC) proteins, 251-262 365-377
Itract) fera, hepatotoxicity of, 195-206 remission in, 365-377
Augmentin, hepatotoxicity of, 157-167 serological marker autoantibodies in, characterization of,
Aut intibodic 339 351
itoimmune diseases, 387-394, 395-405 and severe cholestasis without inflammatory activity, liver
immune hepatitis, 339-351, 395-405 transplantation for, 379-385
| ry biliary cirrhosis, 291-302, 395-405 treatment failure in, 365-377
\ut liver transplantation for, 379-385
{ ‘ t ee l treatmento f, 365-377
)
tolerar I ns tor, 365-377 advances in future directions for , 365-377
tat t t t, therapeutic n children, 365-3
t 65 a citrhosis. 365=377
\ } S—A) comorbid \ditior ind, 365-377
\ut conventional schedules for, 365-377
394 } in elderly, 365-377
' f ) evolving, 365-377
incomplete response to, 365-377
t n postmer iusal women, 365-377
4 pregnanc 365-37
4 suboptimal results of, management of, 365-377
| | 4 tvpe 1, 339
f $4 enetics t 5 63
\ | t \TH 15-31¢ Ove | tvpe 2, 339-351
: type 3. 339
. Autoimmunity
ver t I 5/9-385 induction of, 387-394
itment ot, 365-3 mechanisms of, 38 394
| models of, 325-337 \zathioprine
H ociated with autoimmune polyglandular syndrome, tor autoummune hepatitis, 365-377
microsomal autoantibodies in, 339-351 mechanismo f action of, 365-377
| utoantibodies in, 339-351 Azithromycin
f roant vel I 339 351 cholestasis cause 20) 210
; biochemical features of, 317-324 hepatotoxicity ot, 157-167
classification of, 317-324 Azole antifungals, hepatotoxicity of, 157-167
linical features of, 317-324 Aztreonam, hepatotoxicity of, 157--167
SUBJECT INDEX 1-5
B Carbenicillin, hepatotoxicity of, 157-167
Balloon occluded retrograde transvenous obliteration, for Cascara sagrada, hepatotoxicity of, 195-206
gastric varices, 1-3, 73-82 Caspases, in toxic liver injury, 137-144
Barbiturates, hepatotoxicity of, 168-183 Ceftriaxone, hepatotoxicity of, 157-167
Bentazepam, hepatotoxicity of, 168-183 Celecoxib
Benzodiazepine, hepatotoxicity of, 168-183 hepatotoxicity of, 168-183
Beta blockers, hepatotoxicity of, 168-183 therapeutic potential in cholangiocarcinoma, 303-313
Bile Cell death. See also Necrosis
formation of, 213-226, 251-262 initiation of, 137-144
mechanisms of, 241-249 mitochondria and, 137-144
secretion of programmed. See Apoptosis
drug transporter function and, 123-136 Cell survival, mechanisms of, 137-144
regulation of, 241-249 Cell volume, hepatic and biliary, autocrine regulation of,
Bile acids, metabolism of, regulation of, 115-122
251-262
Bile ducts, terminal, number of, 213-226 Cephalexin, hepatotoxicity of, 157-167
Bile ductules, 213-226 Cephalosporins, hepatotoxicity of, 157-167
Bile salt export pump (BSEP) Cerivastatin, hepatotoxicity of, 168-183
drug substrates for, 123-136 Chaparral leaf, hepatotoxicity of, 195-206
and hepatic drug uptake, 123-136 Chemotherapy, sinusoidal obstruction syndrome caused by,
Biliary epithelium 27-41
diseases targeting, heterogeneity of, 227-240 Children, autoimmune hepatitis in, treatment of, 365-377
functional diversity of, 227-240 Chinese herbal medicines, hepatotoxicity of, 195-206
intrahepatic, functional heterogeneity of, 227-240 Chloramphenicol, hepatotoxicity of, 157-167
morphology of, 227-240 Chlorpromazine, hepatotoxicity of, 168-183
in primary biliary cirrhosis, 291-302 Chlorpropamide, hepatotoxicity of, 168-183
research on, advances in (future directions for), 227-240 Cholangiocarcinoma
Biliary tree cyclooxygenase-2 in, 303-313
anatomy of, 213-226 ERBB-2 in, 303-313
extrahepatic, vascularization of, 227-240 pathogenesis of, animal models of, 303-313
intrahepatic risk factors for, 303-313
anatomy of, 227-240 therapeutic targeting in, 303-313
development of, 213-226 Cholangiocytes
morphological heterogeneity of, 227-240 actin cytoskeleton in, 263-276
three-dimensional architecture of, 213-226 abipoolpotgoyt ico f,r es2p1o1n-s2e1s2 of, 227-240
vascularization of, 227-240
Biliopathy, portal Cl transport in, 241-249
wtirteha tmeexnttr ahoefp,a t4i3c- 58p ortal vein obstruction, 43-58 funecvtailouna tiilo nh etoefr, ogine nveiivtoy anofd. in2 vitro 4()t ools for, 227-240
Bosentan, and hepatic drug transport, 123-136 functions of, 227-240
Bromfenac, hepatotoxicity of, 168-183 large
Budd-Chiari syndrome, 5-14. See a/so Hepatic vein, functional heterogeneity of, 227-240
thrombosis; Obliterative hepatocavopathy morphology of, 227-240
definition of, 15-26 proliferative respons¢ s of, ay 240
imaging in, 5-14 secretionb y
pathophysiology of, 1-3, 5-14 cAMP-independent regulation of, 241-249
terminology for, 15-26 regulation of, 241-249
treatment of, graded approach to, 5-14 reseoan, radcvanhce s in (future directions for), 241-249
Budesonide, for autoimmune hepatitis, 365-377 vesicular trafficking of apical ti
Bupropion, hepatotoxicity of, 168-183 241-249
re small
functional heterogeneity of, 227-24
Calcium channel antagonists morphology otf, 227-240
hepatotoxicity of, 168-183 transport, purinergi signaling in, 241-249, 251-262
and steatohepatitis, 185-194 Cholangiopathy. See a/so AIDS chol hy
Callilepsis laureola, hepatotoxicity of, 195-206 of large ducts, 227-240
Canals of Hering, 213-226 research on, advances in (future directions for), 227-240
Candesartan, hepatotoxicity of, 168-183 of small ducts, 227-240
Captopril, hepatotoxicity of, 168-183 Cholestasis
Carbamazepine azithromycin-induced, 207-210
hepatotoxicity of, 168-183 drug-induced
and steat hepatitis, 185-194 molecular mechanisms of, 123-136
SEMINARS IN LIVER DISEASE/VOLUME 22, NUMBER 4 2002
Cholestasis (continued CTLA-4, soluble, therapeutic applications of, 365-377
research on, advances in (future directions for), 123-136 CTLA4 gene, in autoimmune disease, 353-363
target transporterisn , 123-136 Cyclooxygenase (COX), COX-2
pure, 145-155 in cholangiocarcinoma, 303-313
Cirrhosis inhibitors, hepatotoxicity of, 168-183
hepatk Cyclophosphamide, sinusoidal obstruction syndrome caused
and idiopathic portal hypertension, comparison of, by, 27-41
59-71 Cyclosporin A, and hepatic drug transport, 123-136
and treatment of autoimmune hepatitis, 365-377 Cyclosporine
in surgical | patient, bleeding risk in, 83-96 for autoimmune hepatitis, 365-377
Cl ithromvcin n, hepatotoxicity of, 157-167 and herbal medicines, interactions of, 195-206
Cl idamycin, hepatotoxicity of, 157-167 Cystic fibrosis transmembrane conductance regulator, 123-136
\ lotiazepam, hepatotoxicity of, 168-183 as CAMP-regulated Cl channel, 241-249, 251-262
( lotting factors. See Coagulation factors Cytarabine, hepatotoxicity of, 157-167
Cloxacillin, hepatotoxicity of, 157-167 Cytochrome P-450
Coagulation autoantibodies against, 339-351
inhibitors of, 83-96 CYP3A4 inducerands , herbal medicines, interactionosf ,
intrahepatic, sinusoidal obstruscyndtromie coausned by, 195-206
27-41 CYP2B gene, induction by phenobarbital, nuclear receptor
CAR and, 115-122
clinical applications of, 83-96 CYP2C19, deficiency of, and drug-related hepatotoxicity,
Coagulation cascade, 83-96 145-155
Coagulation disorders CYP2D6, deficiency of, and drug-related hepatotoxicity,
with extrahepatic povreint obastrulctio n, 43-58 145-155
hepatic l involvCe ment in, 1-3, 83-96 CYP2D6 gene, mutation of, 185-194
nvasive pprr oceau;l:oer es ind Q2 96 gene expressi yn
intation, 83-96 in liver, 115-122
nd pregnancy, 83-9 nuclear a PXR and, 115-122
in intracellular hepatic drug metabolism, 123-136
Cytokines
in liver injury, animal models of, 325-337
Coagulation factor manipulations of, therapeutic +O of, 365-377
and sinusoidal obstruction syndron ne, 2/-41
in toxic liver injury, 137 144
£ 23-9 D
Dapsone, hepatotoxicity of, 157-167
Detibrotide, for sinusoidal obstruction syndrome, 27-41
Deflazacort, for autoimmune hepatitis, 365-377
27-41 Desmopressin, for coagulation disorders, 83-96
Diabetes mellitus, d ug treatment of, hepatotoxicity of, 168 183
Diclofenac
and hepatic drug transport, 123-136
tor autoimr ’ } 9 tit ae S hepatotoxicity of, 168 183
Dicloxacillin, hepatotoxicity of, 157-167
|
teatohepatit 185 )4 Disease, and drug-related hepatotoxicity, 145-155
; :
| Uisseminated intravasc ular coagulation (DIC , in liver
|
lisease, 83-96
289 Doxycycline, hepatotoxicity of, 157-167
89 Drug-drug interactions
and drug-related hepatotoxicity, 145-155
ri duced by, pathogenesis of, »772_7_79- 289 and 11 hepatic drug transport,
Drug-herb interactions, 195-206
SY D1 gS. See al specific dru
canalicular trat sport of, regulation of, 123-136
hepatic metabolism of
nmune response t 7-289 initia an 113, 115-122
ot, hepatic transport of, mechanisms of, 123-136
89 and liver, 109-113
SUBJECT INDEX 1-7
reactive metabolites of, detoxification of, deficiency in, and angioarchitecture of, 73-82
drug-related hepatotoxicity, 145-155 bleeding site of, 73-82
Ductal plate system, development of, 213-226 cardiac, pathomorphology of, 73-82
Dysfibrinogenemia
endoscopic obliteration ot, 43-58
clotting factor reduction in, 83-96 with extrahepatic portal vein obstruction, 43-58
in liver disease, 83-96 fundic
balloon-occluded retrograde transvenous obliteration
E for, 73-82
Elderly, autoimmune hepatitis in, treatment of, 365-377 endoscopic sclerotherapy for, 73-82
Emodin, therapeutic potential in cholangiocarcinoma, endoscopic variceal ligation for, 73-82
303-313 pathomorphology of, 73-82
Enalapril, hepatotoxicity of, 168-183 pathomorphology of, 1-3, 73-82
Endoplasmic reticulum (ER), antigens of, autoantibodies treatment of, 1-3
against, 339-351 Gemfibrozil, hepatotoxicity of, 168-183
Endothelin-1, in sinusoidal obstruction syndrome, 27-41 Gene expression, in toxic liver injury, 137-144
Epithelium, functional heterogeneity of, 227-240 Gene therapy, for autoimmune hepatitis, 365-377
Epsilon-aminocaproic acid, indications for, 83-96 Genetic analysis, in complex disease, 353-363
ERBB-2, in cholangiocarcinoma, 303-313 Germander, hepatotoxicity of, 195-206
Erythromycin esters, hepatotoxicity of, 157-167 Glibenclamide
Erythromycin estolate, hepatotoxicity of, 157-167 and hepatic drug transport, 123-136
Esophageal varices hepatotoxicity of, 168-183
angioarchitecture of, 73-82 Gliclazide, hepatotoxicity of, 168-183
bleeding site of, 73-82 Glimepiride, hepatotoxicity of, 168-183
endoscopic injection sclerotherapy for, 73-82 Glipizide, hepatotoxicity of, 168-183
endoscopic obliteration of, 43-58 Glucosidase inhibitors, hepatotoxicity of, 168-183
endoscopic variceal ligation for, 73-82 Glutathione depletion, and hepatic drug tr insport;
with extrahepatic portal vein obstruction, 43-58 123-136
pathomorphology of, 1-3, 73-82 Glutathione S-transferase (GST), type I, deficiency of, ana |
posttreatment, pathology of, 73-82 drug-related hepatotoxicity, 145-14 55
treatment of, 1-3 Glutathione synthetase, deficiency of, and drug-related
Esophagus, normal, angioarchitecture of, 73-82 hepatotoxicity, 145-155
Estrogens, and steatohepatitis, 185-194 Greater celandine, hepatotoxicity of, 195-206
Ethambutol, hepatotoxicity of, 157-167 Griseofulvin, hepatotoxicity of, 157-167
Etodolac, hepatotoxicity of, 168-183 Growth retardation, with extrahepatic portal vein
obstruction, 43-58
F treatment of, 43-58
Factor VIla, recombinant, for coagulation disorders, 83-96
Fansidar, hepatotoxicity of, 157-167 H
Fatty liver, of pregnancy, 83-96 I laloperidol, hepatotoxicity of, 168-183
Felbamate, hepatotoxicity of, 168-183 HELLP syndrome, 83-96
Fenofibrate, hepatotoxicity of, 168-183 Hemostasis, abnormalities of, in liver disease, 83-96
Fialuridine, hepatotoxicity of, 157-167 Heparin, in prevention of sinusoidal obstruction syndr
Fibrates, hepatotoxicity of, 168-183 27-41
Fibrinolysis, in liver disease, 83-96 Hepatic vein
Fibrinolytic system, 83-96 outflow block, 15-26
Flucloxacillin thrombosis, 1-3, 5-14
and hepatic drug transport, 123-136 causes of, 5-14
hepatotoxicity of, 157-167 clinical manifestations of, 5-14
Flucytosine, hepatotoxicity of, 157-167 diagnosis of, 5-14
Fluoxetine, hepatotoxicity of, 168-183 epidemiology of, 5-14
Fluvastatin, hepatotoxicity of, 168-183 histopathology of, 5-14
Fluvoxamine, hepatotoxicity of, 168-183 pathophysiology of, 5—14
Focal nodular hyperplasia, multiple, with malignancy, 97-102 prognosis for, 5-14
Foscarnet, hepatotoxicity of, 157-167 I Lepatic venous pressure gradient, in sinusoidal obstri
Fosinopril, hepatotoxicity of, 168-183
syndrome, 27 4]
Fresh-frozen plasma (FFP), for coagulation disorders, 83-96 Hepatitis
Fusidic acid, hepatotoxicity of, 157-167 acute cholestatic, 145-155
autoimmune. See Autoimmune hepatitis (AIH
G cryptogenic (seronegative), 395-405
Ganciclovir, hepatotoxicity of, 157-167 and treatment of autoimmune hepatitis, 365-3
Gastric vari drug-induced, diagnosis of, difficulties of, 145-155
1-8 SEMINARS IN LIVER DISEASE/VOLUME 22, NUMBER 4 2002
Hepatitis B] diagnosis of, 145-155
chron diagnostic criteria for, 145-155
epidemiology of, $1-S6 epidemiology of, 145-155
treatment of, advances in, $33-S36 advances in (future directions for), 145-155
HBe Ag negative genetic factors in, 145-155
adefovir dipivoxil for, $33-S36 incidence of, 145-155
lamivudine for, $15-S21 prevalence of, 145-155
susceptibility to, 145-155
HBe \g positive
idefovir dipivoxil for, S33-S36 detection of, advances in (future directions for),
lamivudine for, $15—-S21 145-155
HBeAg seroconversion in, $1-S6 terminology for, 145-155
management of, key issues in, $1-S6 drugs and, 109-113
treatment of. See a/so Interferon; Lamivudine occupational, 185-194
advances in, $33-S36 protection against
duration of, and therapeutic effect, $1-S6 pitfalls in, 137-144
goals of, $1-S6 therapeutic possibilities for, 137-144
hepatotoxicity of, 15 7- 167 Herbal hepatotoxicity, 195-206
response to agents causing, 195-206
biochemical, $1-S6 diagnosis of, 195-206
clinical measures of, $1-S6 risk factors for, 195-206
detectioof,n $1-S6 and sinusoidal obstruction syndrome, 27-41
histological, $1—S6 Highly active antiretroviral therapy (HAART)
monitorionf,g 51—-S6 hepatotoxicity of, 157-167
serological, $1 56 and steatohepatitis, 185-194
standardization of, need for, $1-S6 HMG-CoA reductase inhibitors, hepatotoxicity of, 168-183
time-based definitiofo,n $1-S6 Human immunodeficiency virus (HIV), antiretroviral
virological, $1-S6 therapy for, hepatotoxicity of, 157-167
YMDD mutation in, $15 S21, $23-S31, $33-S36 Hydralazine, hepatotoxicity of, 168-183
HepatitB ivisru s (HBV Hypersplenism
DNA, assays for, $1-S6 with extrahepatic portal vein obstruction, 43-58
drug resistance in, S23-S31 treatment of, 43-58
+7 >
lecular mechanisms of, 523-531 with idiopathic portal hypertension, 59-71
aynamic nd kinetics of
, > >
errec 1cVveE pment of dru resistance, 523-$31 I
>> —@
ttect o1 ea 923-931 Ibuprofen, hepatotoxicity of, 168-183
8323-831 Idoxuridine, hepatotoxicity of, 157-167
t side resistance, $23-S31 [mipenem, hepatotoxicity of, 157-167
Immune response
§932-S 31 liver-specific, transgenic mice for study of, 325-337
$23-S31 in vertebrates, 387-394
} t. $23-S31 Immune response genes
1 492 S31 of MHC, 353-363
re C24
outside MHC, 353-363
11
ri \ Immune status, with extrahepatic portal vein obstruction,
339-35]
le marré Immune system, genetic variations in, and drug-related
t 1()3 10 hepatotoxicity, 145-155
Hey 1L D vodies 1n, 33> 9-35> ] Immunocyte activation, mechanisms of, 365-3
Hi HCC), in hepatB)i ,p treivesnt i
Indomethacin, hepatotoxicity of, 168-183
~ S13 Infections, and primary biliary cirrhosis, 291-302
Hepatoce \ e, 14{ 5-115655 Inferior vena cava
Hepat tv. § membranous obstruction of, 15-26
; tir hia thrombosis, 1-3,> 15-26
biochemic me clinical features f, 15-26
11.1
lial I diagnosis of, 15-26
lrug-re r .) epidemiology of, 15-26
K ( 14 ( etiology of, 15-26
lll l + twpes i pathophysiology of, 15-26
prognosis tor, 15-26
charact STIC
cop treatment of, 15-26
vitl Infliximab, hepatotoxicity of, 168--183
SUBJECT INDEX i-9
Insulin, human, hepatotoxicity of, 168-183 Liver disease
Insulin resistance syndrome, and nonalcoholic steatohepatitis, chronic, definition of, 145-155
185-194 drug-induced, diagnosis of, difficulties of, 145-155
Interferon, for hepatitis B, $1-S6, S7-S13 and drug-related hepatotoxicity, 145-155
efficacy versus tolerability of, S7-S13 Liver failure
long-term outcomes with, $7-S13 after bone marrow transplantation, in patient with
nonresponse to, predictors of, S7-S13 hepatitis C, 103-107
response to fulminant, in autoimmune hepatitis, 395-405
durability of, S7-S13 Liver injury
predictors of, S7-S13 acute
and slowed disease progression, $7-S13
cholestatic, 145-155
Irbesartan, hepatotoxicity of, 168-183 mixed pattern, 145-155
Isabgol, hepatotoxicity of, 195-206 cytokine models of, 325-337
Ischemia, effects on actin cytoskeleton, 263-276 drug-related
Isoniazid, hepatotoxicity of, 157-167 definition of, 145-155
diagnostic criteria for, 145-155
Liver transplantation
Jin Bu Huan, hepatotoxicity of, 195-206 for autoimmune hepatitis, 365-377, 379-385, 3
bleeding risk in, 83-96
K for Budd-Chiari syndrome, 5-14
K ava, hepatotoxicity of, 195-206 and lamivudine for hepatitis B, $15-S21
K idney, in sinusoidal obstruction syndrome, 27-41 for sinusoidal obstruction syndrome, 27-41
Losartan, hepatotoxicity of, 168-183
3 Lovastatin, hepatotoxicity of, 168-183
B -Lactam antibiotics, hepatotoxicity of, 157-167
L
amivudine M
for hepatitis B, S1-S6 Macrolides, hepatotoxicity of, 157-167
clinical experience with, $15-S21 Magnetic resonance imaging (MRI)
guidelines for, $15-S21 of hepatic vein thrombosis, 5-14
in HBeAg-negative patients, $15-S21 of obliterative hepatocavopathy, 15-26
in HBeAg-positive patients, $15-S21 in sinusoidal obstruction syndrome, 27-41
HIV coinfection and, $15-S21 Ma-Huang, hepatotoxicity of, 195-206
primary end point for, $15-S21 Major histocompatibility complex (MHC)
response to and clinical phenotype, 353-363
biochemical, $15-S21 disease encoded by, molecular models of, 353-363
durability of, $15-S21 in disease susceptibility and resistance, 353-363
serological, $15-S21 genes of, 353-363
virological, S1 5-S2 1 MDR1 gene, regulation of, by nuclear receptors PXR and
safety of, $15-S21 CAR, 115-122
and transplantation, $15-S21 Mebendazole, hepatotoxicity of, 157-167
viral resistance to, $23-S31 Meloxicam, hepatotoxicity of, 168-183
hepatotoxicity of, 157-167 Membrane fluidity, and hepatic drug transport, 123-136
amotrigine, hepatotoxicity of, 168-183 Menopausal status, and treatment of autoimmune hepatitis,
vaxatives, herbal, hepatotoxicity of, 195-206 365-377
.eflunomide, hepatotoxicity of, 168-183 6-Mercaptopurine, for autoimmune hepatitis, 365-377
selomyosarcoma, hepatic, high-grade, and multiple focal Meropenem, hepatotoxicity of, 157-167
nodular hyperplasia, 97-162 Metformin, hepatotoxicity of, 168-183
ipid-lowering agents, hepatotoxicity of, 168-183 Methotrexate, steatohepatitis caused by, 1
Aver Methyldopa
biopsy of hepatotoxicity of, 168-183
bleeding risk in, 83-96 and steatohepatitis, 185-194
in sinusoidal obstruction syndrome, 27-41 Metronidazole, hepatotoxicity of, 157-167
cut surface of, with idiopathic portal hypertension, 59-71 Mice. See Transgenic mice
development of, 213-226 Microarray technology, in research on drug transport and
form of, with idiopathic portal hypertension, 59-71 toxicity, 123-136
histopathology of, with idiopathic portal hypertension, 59-71 Microsomal autoantibodies
macroscopic findings in, with idiopathic portal in autoimmune hepatitis associated with autoimmune
hypertension, 59-71 polyglandular syndrome, 339-351
size of, with idiopathic portal hypertension, 59-71 diseases associated with, 339-351
vascular changes of, with idiopathic portal hypertension, hepatitis C-associated, 339-351
hepatitis D-associated, 339-351
1-10 SEMINARS IN LIVER DISEASE/VOLUME 22, NUMBER 4 2002
patotoxicity of, 168-183 Organic cation transporter
hepat ty of, 157-167 drug substrates for, 123-136
Mitochondria, in toxic liver injury, 137-144 and hepatic drug uptake, 123-136
Molecular footprint hypothesis, 353-363 Overlap syndromes, antinuclear antibodies and, 339-35
Monoamine oxidase inhibitors (MAOIs), hepatotoxicity of, Oxacillin, hepatotoxicity of, 157-167
Oxaprozin, hepatotoxicity of, 168-183
r receptors PXR and Oxidative stress, drug-related, in toxic liver injury,
137-144
g substr for, 123-136 P
1 hepatic drug uptake, 123-136 Paroxetine, hepatotoxicity of, 168-183
Multidrug resistance-1 P-glycoproteit Penicillins, hepatotoxicity of, 157-167
g ratest or, 123-136 Pennyroyal, hepatotoxicity of, 195-206
i hepatic drug uptake, 123-13¢ Pentamidine, hepatotoxicity of, 157-167
Multidrug resistant proteins, and hepatic drug uptake, 123-136 Pentoxifylline, and sinusoidal obstruction syndrome, 27-41
Mycophenolate mofetil, for 1utoimmune hepatitis, 365-377 Perhexiline maleate, steatohepatitis caused by, 185-194
Peribiliary glands, 213-226
utioning regimens s for, and prevention of sinusoida*l Peritoneovenous shunt, for sinusoidal obstruction syndrome,
bstruction syndrome, 27-41 27-41
lal obstructic 17-41 Permissive gene pool, and autoimmune hepatitis, 353-363
My roliter c vein thrombosis Peroxisome proliferator activator receptor(s) (PPAR), and
nonalcoholic steatohepatitis, 185-194
5 +
Phenytoin, hepatotoxicity of, 168-183
N Pioglitazone, hepatotoxicity of, 168-183
Nafi 1 cit t. 157-167 Piroxicam, hepatotoxicity of, 168-183
Naproxet epatot tv ot, 168-183 Plant toxins, and sinusoidal obstruction syndrome, 27-41
Neer n toxic live yv, 137-144 Platelet disorders, in liver disease, 83-96
Netazodone, hepatotoxicity of, 168-183 Platelet transfusion, for coagulation disorders, 83-96
Niclotolan, hepatoto v of, 157-16 Portal biliopathy
Nicotinic acid patotoxicity ot, 168-183 with extrahepatic portal vein obstruction, 43-58
N esulide epat yxicity of, 168-183 treatment of, 43-58
Nitrot toin, hepatotoxicity of, 157-167 Portal fibrosis, noncirrhotic, 1-3
N ucol Cc ste epati NASH Portal hypertension
R \¢ 185 194 idiopathic, 1-3, 59-71
] r d. 185-194 and cirrhosis, comparison of, 59-71
1 exp ire d. 185-194 clinical features of, 59-71
Nor le d lo erse criptas hibitors definition of, 59-71
patoto v of, 157-16 diagnostic criteria for, 59-71
N teroidal la v drugs (NSAIDs epidemiology of, 59-71
i hepa g trans] 123-136 etiologic considerations in, 59-71
if HA 183 hepatic veins in, 59-71
N re patot city « 57-16 histopathology of, 59-71
N ) t T pat ar liver pathology in, 59-71
morbid anatomy of, 59-71
N | S tase to portal fibrosis in, 59-71
i t 57 16 signs and symptoms of, 59-71
N | attine B. viral resistar A vascula3 r ch| anges in, 5e9w-e7 1
89 3-S3 noncirrhotic, 1-3, 43-58
Nucleot egrad d ptake pathwayfso r, 251-26 Portal vein obstruction, extrahepatic, 1-3, 43-58
N l \ verse hepatic drug in adults, etiology of, 43-58
145-155 animal models of, 43-58
in children, etiology of, 43-58
O clinical presentation of, 43-58
Obliterative hepat vopathy, 1-3, 15-26. § Interior diagnosis of, 43-58
ena Ca hromb« S etiolofo, g43y-5 8
Olanzapine epatotoxicity of, 168-183 hemodynamic studies in, 43-58
Or anion transporting polypeptide-2 (Oatp2 hepatic functional status with, 43-58
regulationb y PXR, 115-122 hypercoagulable states and, 43-58
Organic anion transporting polypeptides OATP/Oatp pathology of, 43-58
drug substrates tor, 123-13¢ pathophysiology of, 43-58
and hepatic ar pharmacotherapy in, 43-58